Skip to main content

Midodrine Pregnancy and Breastfeeding Warnings

Brand names: Orvaten, ProAmatine

Medically reviewed by Drugs.com. Last updated on Sep 16, 2024.

Midodrine Pregnancy Warnings

Use is not recommended and this drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

US FDA pregnancy category: C

Comments: Adequate methods of contraception should be encouraged.

Animal studies have revealed increased rate of embryo resorption, reduced fetal body weight, and decreased fetal survival. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Midodrine Breastfeeding Warnings

Use should be avoided; otherwise, caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

See also

References for pregnancy information

  1. (2001) "Product Information. ProAmatine (midodrine)." Roberts Pharmaceutical Corporation
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."

References for breastfeeding information

  1. (2001) "Product Information. ProAmatine (midodrine)." Roberts Pharmaceutical Corporation
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer